Regulation

Republicans Target November Hemp THC Ban With Three Amendments

mm
Add MyCannabis.com to your preferred sources on Google

The hemp industry is less than six months from a scheduled federal crackdown on intoxicating hemp products, and three House Republicans are now attempting to use a must-pass spending bill to stop it.

Reps. Andy Barr (R-KY), Russell Fry (R-SC), and James Comer (R-KY) filed separate amendments to a pending fiscal year 2027 agriculture appropriations bill currently before the House Rules Committee. The three proposals diverge sharply in scope: one would build an entirely new regulatory framework for hemp THC products; one would delay enforcement for two years; and one would cut off the federal funds needed to enforce the ban at all. The Rules Committee is expected to decide in the coming days which, if any, can proceed to a House floor vote.

What the Three Amendments Would Do

Barr’s proposal is the most detailed. The 25-page measure, circulated under the name Lawful Hemp Protection Act, would raise the federal threshold for legal hemp-derived products from the current 0.3 percent delta-9 THC to 1 percent, measured against the finished consumer product rather than raw plant material. That distinction matters: a flower or extract at various processing stages can test above a finished product’s final THC content, and the current standard has created compliance ambiguity throughout the supply chain. Under Barr’s approach, it’s the packaged item on the shelf that must meet the limit.

The proposal would also construct a federal regulatory structure that doesn’t currently exist. Hemp beverages would come under a three-tier distribution system modeled on alcohol, administered by the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau. Other hemp consumables — gummies, tinctures, capsules, inhalables — would fall under FDA oversight as food products. Both categories would face a 21-plus age requirement, mandatory THC content labeling, and required health warnings. Within 18 months of enactment, the FDA would be required to set maximum allowable cannabinoid limits per serving through a formal rulemaking process. A 5 percent fee on most hemp consumables and a per-milligram charge on hemp beverages would fund enforcement and regulation.

Barr’s submission carries a procedural problem that could sink it before it gets a hearing. The Rules Committee instructed members to format amendments specifically to the text of the appropriations bill, and Barr’s submission appears to have been filed as a standalone bill text rather than as a properly drafted floor amendment. The committee warned it would not review noncompliant submissions. That formatting gap may reflect a document drafted for a forthcoming standalone bill rather than a deliberate workaround, but the Rules Committee’s directions leave little room for exceptions.

Fry’s amendment is far simpler: a two-year delay in the recriminalization effective date, buying the industry time while Congress works toward a longer-term framework. Comer’s takes a different angle — a spending rider that would block federal funds from being used to enforce the hemp restrictions at all, effectively neutralizing the ban without rewriting the underlying law. The coalition of opposition that has formed around Barr’s broader regulatory effort — including segments of the distilled-spirits industry, licensed marijuana businesses, and prohibitionist groups — gives some indication of how contested a regulatory fix would be even if it cleared the procedural hurdles.

The Deadline and Its Origins

The November 12, 2026 cutoff dates back to a government funding package President Trump signed on November 12, 2025. Tucked into that legislation was a provision redefining federally legal hemp. Under the new standard, a product would need to contain fewer than 0.4 milligrams of total THC per container — a threshold that effectively bans most hemp-derived gummies, beverages, and vaping products currently on shelves. The provision also bans hemp products containing synthetic cannabinoids such as delta-8 THC, or cannabinoids not naturally produced by the cannabis plant.

The 2018 Farm Bill had set the baseline the industry was built on — hemp derivatives under 0.3 percent delta-9 THC on a dry-weight basis. That definition created the market for intoxicating hemp products; what passed in November 2025 rewrote it entirely.

The industry’s primary attempt to undo those restrictions through the 2026 Farm Bill failed. The House passed that measure in late April 2026 without any language addressing the hemp THC ban, after bipartisan amendments were withdrawn before floor consideration. A Hemp Planting Predictability Act introduced in January 2026 — which would push the effective date back two years — has been sitting without a committee hearing since. Texas hemp retailers have been living with the whipsaw effect of the accumulated enforcement ambiguity in the meantime.

The White House Signal and the Political Math

Trump has been more publicly engaged on this issue than on most cannabis policy questions. In an April 2026 post on Truth Social, he called on Congress to act to preserve access to full-spectrum CBD while restricting products that “pose Health risks.” White House domestic policy officials also sent Barr’s office a letter transmitting suggested legislative text, signaling the administration wants some version of a hemp regulatory fix — though what the White House would actually accept remains undisclosed.

That engagement gives Republicans political cover to move, but it hasn’t moved the structural math. Sen. Ted Cruz recently assessed the legislative path to averting the ban as “uphill.” The Marijuana Policy Project has said it considers blocking the ban entirely before November 2026 unlikely, though a partial carve-out for specific product categories such as beverages could still be achievable. The federal drug strategy released earlier this year signaled enforcement intent on unregulated intoxicating hemp products — which sharpens the stakes if November arrives without a fix.

The appropriations process is one of the few procedural vehicles still open. For farmers holding last year’s crop in storage and retailers already reconfiguring their product lines, the Rules Committee’s decision on these amendments will signal whether Congress is treating the November deadline as a policy problem or a political abstraction.

Ava Morales is an AI-generated analyst at MyCannabis.com, covering U.S. cannabis regulation with a focus on state-by-state legalization, medical programs, and consumer compliance. Her work helps readers navigate the fragmented legal landscape governing cannabis access, possession, and use across the United States.

With a structured and explanatory approach, Ava tracks legislative changes, ballot initiatives, and regulatory guidance affecting both medical and recreational cannabis markets. She emphasizes clarity over speculation, distinguishing clearly between enacted law, proposed reforms, and local enforcement realities so readers understand what is permitted in their jurisdiction today.

Articles authored by Ava Morales are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, neutrality, and responsible reporting on cannabis laws in regulated U.S. markets.